48,100 Shares in Envista Holdings Co. (NYSE:NVST) Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new position in shares of Envista Holdings Co. (NYSE:NVST) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,100 shares of the company’s stock, valued at approximately $1,157,000.

Several other institutional investors and hedge funds have also bought and sold shares of NVST. Headinvest LLC bought a new position in shares of Envista in the third quarter worth about $28,000. Fifth Third Bancorp raised its holdings in Envista by 98.1% in the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock valued at $30,000 after buying an additional 621 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Envista during the 3rd quarter valued at approximately $47,000. Covestor Ltd increased its position in Envista by 33.9% during the 3rd quarter. Covestor Ltd now owns 2,462 shares of the company’s stock valued at $69,000 after purchasing an additional 624 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Envista by 69.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,516 shares of the company’s stock valued at $126,000 after purchasing an additional 1,844 shares during the period.

Envista Stock Up 0.6 %

NVST stock opened at $20.23 on Wednesday. Envista Holdings Co. has a fifty-two week low of $18.95 and a fifty-two week high of $39.28. The business’s 50 day moving average price is $21.08 and its two-hundred day moving average price is $22.79. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.90 and a current ratio of 2.23. The company has a market capitalization of $3.48 billion, a price-to-earnings ratio of -33.16, a price-to-earnings-growth ratio of 3.73 and a beta of 1.35.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.04). The company had revenue of $645.60 million during the quarter, compared to analysts’ expectations of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.52 EPS. As a group, analysts forecast that Envista Holdings Co. will post 1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on NVST. TheStreet downgraded shares of Envista from a “c” rating to a “d+” rating in a research report on Wednesday, February 7th. UBS Group began coverage on Envista in a research note on Friday, January 5th. They set a “neutral” rating and a $26.00 price objective on the stock. Leerink Partnrs reaffirmed an “underperform” rating on shares of Envista in a research report on Monday, February 26th. SVB Leerink started coverage on shares of Envista in a research note on Monday, February 26th. They set an “underperform” rating and a $19.00 price target on the stock. Finally, William Blair cut Envista from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Envista has a consensus rating of “Hold” and an average price target of $29.60.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.